Sonoma Pharmaceuticals, Inc. (SNOA) Jun 2024 Earnings Report
Sonoma Pharmaceuticals, Inc.: Investment Report
Overview
Sonoma Pharmaceuticals, Inc. is a global healthcare leader developing and producing patented Microcyn technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. With a strong product portfolio and a growing revenue trend, this report provides an in-depth analysis of the company's financial performance, growth prospects, and future potential.
Core Metrics
- Current price: $0.192 (USD)
- 52-week high: $1.22 (USD)
- 52-week low: $0.12 (USD)
- Market Cap: $3,604,531 (USD millions)
- P/E Ratio: N/A
- Earnings per Share: -$0.82 (USD)
- 50-day average: $0.1786 (USD)
- 200-day average: $0.2876 (USD)
- Analyst Recommendations: Strong Buy (2 analysts)
Financial Performance
Sonoma Pharmaceuticals has reported a revenue growth of 14% in Q4 2024 compared to Q4 2023, and a gross profit margin improvement of 3% in FY 2024 compared to FY 2023. The company has also shown an improvement in net loss, with an 18% reduction in Q4 2024 compared to Q4 2023, and a 6% reduction in FY 2024 compared to FY 2023. However, the company's cash flow remains a concern, with a negative operating cash flow of $2,398,000 and a negative free cash flow of $2,053,125.
Growth Prospects
The company's product portfolio, including Lumacyn, Regenacyn, Reliefacyn, and others, has significant growth potential, particularly in the animal health care and wound care segments. The recent announcement of MicrocynAH for animal health care being available through Menards Home Improvement Stores is a positive development for the company. Additionally, the company's focus on expanding its distribution channels and increasing its marketing efforts could further drive revenue growth.
News and Updates
The company has reported its fiscal year and fourth-quarter 2024 financial results, showing revenue growth and improvement in gross profit margin. Recent news articles have highlighted the company's stock price fluctuations and analyst recommendations. The company has also announced the availability of MicrocynAH for animal health care through Menards Home Improvement Stores.
Upgrades and Downgrades
Ladenburg Thalmann initiated coverage on the stock with a Buy rating in September 2023. Maxim Group downgraded the stock to Hold from Buy in March 2018. Benchmark initiated coverage with a Speculative Buy rating in December 2017.
Summary
Sonoma Pharmaceuticals, Inc. has shown revenue growth and improvement in gross profit margin, despite facing cash flow concerns. The company's product portfolio has significant growth potential, particularly in the animal health care and wound care segments. With a strong analyst recommendation and recent positive developments, this stock may be an attractive opportunity for investors looking for growth potential in the healthcare sector. However, investors should closely monitor the company's cash flow and financial performance to ensure a sustainable growth trajectory.
Disclosures
The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.